Skip to main content

Diabetes Complications More Common in Patients Not Living in Urban Areas

Medically reviewed by Carmen Pope, BPharm. Last updated on March 27, 2024.

By Lori Solomon HealthDay Reporter

WEDNESDAY, March 27, 2024 -- Adults with diabetes living in small towns are disproportionately impacted by complications of diabetes, according to a study published online Feb. 22 in Diabetes Care.

Kyle Steiger, M.D., from the Mayo Clinic in Rochester, Minnesota, and colleagues used the OptumLabs Data Warehouse to identify 2.9 million U.S. commercially insured adults and Medicare Advantage beneficiaries with diabetes (January 2012 through December 2021) to compare the risk for diabetes complications in remote areas (population <2,500), small towns (population 2,500 to 50,000), and cities (population >50,000).

The researchers found that compared with residents of cities, residents of remote areas had greater hazards of myocardial infarction (hazard ratio [HR], 1.06) and revascularization (HR, 1.04). But residents of remote areas had a lower risk for hyperglycemia (HR, 0.90) and stroke (HR, 0.91). Residents of small towns had greater hazards of hyperglycemia (HR, 1.06), hypoglycemia (HR, 1.15), end-stage kidney disease (HR, 1.04), myocardial infarction (HR, 1.10), heart failure (HR, 1.05), amputation (HR, 1.05), other lower-extremity complications (HR, 1.02), and revascularization (HR, 1.05) compared with residents of cities, but they had a lower risk for stroke (HR, 0.95). Residents of remote areas versus those living in small towns had lower hazards of hyperglycemia (HR, 0.85), hypoglycemia (HR, 0.92), and heart failure (HR, 0.94). There was no geographic variation in the risk for retinopathy and atrial fibrillation/flutter.

"While our study didn’t address why these differences exist, we do know that people living outside of city areas are less likely to receive care from diabetes specialists, to receive diabetes self-management education, and to be monitored for diabetes complications," coauthor Esa Davis, M.D., from the University of Maryland in Baltimore, said in a statement. "Our research builds on this foundational evidence to demonstrate a possible impact that these differences have on preventable diabetes complications."

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Read this next

Semaglutide Cuts Risk for Kidney Outcomes, Death in CKD With T2DM

FRIDAY, May 31, 2024 -- For patients with type 2 diabetes and chronic kidney disease, semaglutide reduces the risk for clinically important kidney outcomes and death from...

Demographic, Clinical, Financial Factors Tied to GLP-1 Agonist Discontinuation

WEDNESDAY, May 29, 2024 -- Specific demographic, clinical, and financial characteristics are associated with glucagon-like peptide 1 (GLP-1) receptor agonist discontinuation...

GLP-1 Receptor Agonist Dispensing Up From 2020 to 2023 for Teens, Young Adults

WEDNESDAY, May 22, 2024 -- For adolescents and young adults, glucagon-like peptide-1 receptor agonist (GLP-1 RA) dispensing increased from 2020 to 2023, according to a research...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.